But could this recent investment bubble—$209 million since April 2013—be a repeat of the 1990s, in which a similar surge in investments in gene therapy companies came crashing down when the clinical results could not support the hype? Not according to James Wilson, PhD, Editor-in-Chief of Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The current gene therapy field is quite robust and is grounded in strong science, improved technology, and better clinical targets, says Dr. Wilson in the article “Bulls, Bubbles, and Biotech,” available free on the Human Gene Therapy website.
“While there are admittedly some superficial similarities to the frothy atmosphere that existed in the mid-to late 1990s in this space, I contend that the current state of affairs in cell and gene therapy is very different from what was in place when the bubble burst in 2000,” says Dr. Wilson, Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia. “The scientific foundation of the field is much more solid in 2013 than it was in the year 2000.”
About the Journal
Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journal, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, new in 2013, publishes data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of content for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.